CD274 and cancer: The recently presented KEYNOTE 355 trial that compared pembrolizumab vs. placebo in addition to chemotherapy for metastatic TNBC in the first-line setting also demonstrated a statistically significant improvement in PFS in the pembrolizumab arm but only in PD-L1 positive cancers (CPS ≥ 10 using the 22C3 assay)25.